- Home
- AVIR vs SIGA Comparison
AVIR vs SIGA Comparison
Compare AVIR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | SIGA |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 401.0M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AVIR | SIGA |
|---|---|---|
| Price | $5.76 | $5.24 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 577.0K | ★ 817.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.45% |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | ★ N/A | $16.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $4.81 |
| 52 Week High | $6.45 | $9.62 |
Technical Indicators
Market Signals| Indicator | AVIR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 42.36 |
| Support Level | $3.33 | $4.81 |
| Resistance Level | $6.45 | $6.98 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 63.36 | 63.61 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.